BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25872548)

  • 1. Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries.
    Gelvan A; Risum S; Langer SW
    Dan Med J; 2015 Apr; 62(4):A5033. PubMed ID: 25872548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors associated with interventional bronchoscopy in lung cancer.
    Guibert N; Mazieres J; Lepage B; Plat G; Didier A; Hermant C
    Ann Thorac Surg; 2014 Jan; 97(1):253-9. PubMed ID: 24094520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
    Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
    J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleeve lobectomy as an alternative to pneumonectomy in patients with operable lung cancer.
    Kasprzyk M; Dyszkiewicz W; Piwkowski C; Brudlo M; Galecki B; Gabryel P; Gasiorowski L
    Neoplasma; 2013; 60(1):62-7. PubMed ID: 23067218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
    Mansour Z; Kochetkova EA; Santelmo N; Ducrocq X; Quoix E; Wihlm JM; Massard G
    Ann Thorac Surg; 2008 Jul; 86(1):228-33. PubMed ID: 18573428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
    Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
    Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
    Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?
    Van Meerbeeck JP; De Pauw R; Tournoy K
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):199-206. PubMed ID: 18279061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.
    Ambrogi MC; Fanucchi O; Dini P; Melfi F; Davini F; Lucchi M; Massimetti G; Mussi A
    Eur Respir J; 2015 Apr; 45(4):1089-97. PubMed ID: 25700387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
    J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.
    Shin JY; Yoon JK; Marwaha G
    Lung; 2018 Jun; 196(3):351-358. PubMed ID: 29550987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcategorization of resectable non-small cell lung cancer involving neighboring structures.
    Sakakura N; Mori S; Ishiguro F; Fukui T; Hatooka S; Shinoda M; Yokoi K; Mitsudomi T
    Ann Thorac Surg; 2008 Oct; 86(4):1076-83; discussion 1083. PubMed ID: 18805135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years.
    van der Drift MA; Karim-Kos HE; Siesling S; Groen HJ; Wouters MW; Coebergh JW; de Vries E; Janssen-Heijnen ML
    J Thorac Oncol; 2012 Feb; 7(2):291-8. PubMed ID: 22157366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.